Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor

Arthritis and Rheumatism

Volumn 65, Issue 4, 2013, Pages 1043-1054

  Jacob, Chaim O ^a   Yu, Ning ^a   Guo, Shunhua ^a   Jacob, Noam ^a   Quinn III, William J ^b   Sindhava, Vishal ^b   Cancro, Michael P ^b   Goilav, Beatrice ^c   Putterman, Chaim ^d   Migone, Thi Sau ^e   Stohl, William ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; CD19 ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; INTROGRESSION; KIDNEY DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; WILD TYPE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-CELL MATURATION ANTIGEN; B-LYMPHOCYTE SUBSETS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, CONGENIC; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN;

EID: 84875734465     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37846     Document Type: Article

References (52)

1. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
2. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.
3. Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000; 192: 129-35.
4. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S,. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192: 953-64.
5. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192: 1453-65.
6. Rolink AG, Tschopp J, Schneider P, Melchers F,. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002; 32: 2004-10.
7. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-9.
8. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
9. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-4.
10. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-710.
11. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-9.
12. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
13. Cheema GS, Roschke V, Hilbert DM, Stohl W,. Elevated serum B lymphocyte stimulator levels in patients with systemic immune- based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9.
14. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-86.
15. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-9.
16. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W,. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006; 8: R6.
17. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand Mixed 2328 mice deficient in BAFF. J Immunol 2006; 177: 2671-80.
18. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 2002; 17: 515-24.
19. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116: 724-34.
20. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
21. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al, for the BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
22. Stohl W, Hilbert DM,. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 2012; 30: 69-77.
23. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al, on behalf of the BLISS-52 and BLISS -76 Study Groups. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328-37.
24. Xu S, Lam DP,. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001; 21: 4067-74.
25. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91-7.
26. Sasaki Y, Casola S, Kutok JL, Rajewski K, Schmidt-Supprian M,. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004; 173: 2245-52.
27. Shulga-Morskaya S, Dobles M, Walsh ME, Ng LG, Mackay F, Rao SP, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004; 173: 2331-41.
28. Harless SM, Lentz VM, Sah AP, Hsu BL, Clise-Dwyer K, Hilbert DM, et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol 2001; 11: 1986-9.
29. Von Bulow GU, van Deursen JM, Bram RJ,. Regulation of the T-independent humoral response by TACI. Immunity 2001; 14: 573-82.
30. Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001; 2: 638-43.
31. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS,. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18: 279-88.
32. Kanswal S, Katsenelson N, Selvapandiyan A, Bram RJ, Akkoyunlu M,. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL. J Immunol 2008; 181: 976-90.
33. Ou X, Xu S, Lam KP,. Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cells survival. Proc Natl Acad Sci U S A 2012; 109: 15401-6.
34. Tsuji S, Cortesao C, Bram RJ, Platt JL, Cascalho M,. TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood 2011; 118: 5832-9.
35. Jacob CO, Zang S, Li L, Ciobanu V, Quismorio F, Mazutani A, et al. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand Mixed 2328 mice. J Immunol 2003; 171: 1564-71.
36. Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, et al. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009; 182: 2532-41.
37. Jacob N, Guo S, Mathian A, Koss MN, Gindea S, Putterman C, et al. B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol 2011; 186: 4984-93.
38. Scholz JL, Crowley JE, Tomayko MM, Steinel N, O'Neill PJ, Quinn WJ III, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A 2008; 105: 15517-22.
39. Jacob CO, Guo S, Jacob N, Pawar RD, Putterman C, Quinn WJ III, et al. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum 2012; 64: 1610-9.
40. Yang M, Hase H, Legarda-Addison D, Varughese L, Seed B, Ting AT,. BCMA, the receptor for APRIL and BAFF, induces antigen presentation in B cells. J Immunol 2005; 175: 2814-24.
41. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, et al. The dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180: 3655-9.
42. Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD,. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J Immunol 2011; 186: 6136-47.
43. Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 2000; 192: 1677-83.
44. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 286-97.
45. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-53.
46. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-98.
47. Huard B, Schneider P, Mauri D, Tschopp J, French LE,. T cell costimulation by the TNF ligand BAFF. J Immunol 2001; 167: 6225-31.
48. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173: 807-17.
49. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
50. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al, for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
51. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011-6.
52. Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol 2011; 186: 4223-33.